The feasibility of utilizing chest imaging and pulmonary function testing, including DLCO measurement, for monitoring HER2+ or HER2-low metastatic BC patients receiving T-DXd has been investigated, with promising results indicating that such monitoring may prevent delays in treatment for patients suspected of having ILD. This evidence concerns the gene ERBB2 and breast cancer.